indiabrand.org 
In India, flibanserin is marketed under the brand name Addyi. This medication is primarily prescribed for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It functions by modulating neurotransmitters in the brain, aiming to improve sexual desire. Consult with a healthcare provider for information on dosage and potential side effects associated with Addyi.
Brands to consider
Addyi
Addyi is a notable brand of flibanserin, specifically approved for the treatment of premenopausal women experiencing hypoactive sexual desire disorder (HSDD) in India. This medication acts as a serotonin receptor agonist and antagonist, targeting the neurological factors contributing to low sexual desire. Clinical studies demonstrate its efficacy, with many users reporting improved sexual desire and satisfaction. Addyi is taken daily, reflecting a commitment to consistent management of HSDD. It is essential to consult with a healthcare provider to discuss its suitability for individual health needs.
Fliban
Fliban is a notable brand of Flibanserin in India, specifically targeting hypoactive sexual desire disorder (HSDD) in premenopausal women. Clinical studies highlight its effectiveness in improving sexual desire and overall sexual satisfaction. Manufactured under stringent quality controls, Fliban adheres to regulatory standards, ensuring safety for consumers. Its unique mechanism of action, which modulates neurotransmitters, distinguishes Flibanserin from other treatments available in the market. Considering these benefits, Fliban may be an option for those exploring solutions for HSDD.
Fibanser
Fibanser is a notable brand of flibanserin available in India, primarily indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its formulation targets the central nervous system and works by modulating neurotransmitters to increase sexual desire. Users may appreciate the extensive research supporting its safety and efficacy, with clinical trials demonstrating its positive impact on sexual satisfaction. The accessibility of Fibanser in pharmacies across India further enhances its appeal for those seeking reliable treatment options for HSDD.
Filban
Filban offers a reliable option for individuals seeking treatment for Hypoactive Sexual Desire Disorder (HSDD) in India. As an approved brand of flibanserin, it provides a targeted approach to managing low sexual desire in women. The formulation ensures consistent dosing and effectiveness, which is crucial for achieving desired outcomes. Access to Filban can facilitate discussions with healthcare providers about treatment options, ensuring your health needs are met.
Lovegra
Lovegra is a notable brand of flibanserin available in India, designed specifically for women dealing with hypoactive sexual desire disorder (HSDD). This medication works by targeting serotonin receptors in the brain, which can help enhance sexual desire and improve overall sexual satisfaction. Lovegra is often recommended for those seeking a solution to low libido, especially when traditional treatments have not been effective. With its well-documented efficacy and established safety profile, Lovegra presents a reliable option for women looking to address their sexual health concerns.
Purpose and Usage
Flibanserin, marketed under the brand name Addyi in India, is primarily used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. The medication functions as a serotonin receptor agonist and antagonist, affecting brain chemicals involved in sexual desire. Your healthcare provider may prescribe it to help improve sexual desire when low sexual libido is not due to medical or psychiatric conditions. Safe and effective use of flibanserin requires adherence to guidelines regarding alcohol consumption and potential side effects.
Approval Status
Flibanserin, marketed under the brand name Addyi, is approved in India for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval underscores the growing emphasis on women's sexual health in the Indian pharmaceutical market. The drug operates by modulating neurotransmitter levels in the brain, aiming to enhance sexual desire. The regulatory body responsible for this approval in India is the Drug Controller General of India (DCGI).
Potential Side Effects
Flibanserin, marketed under the brand name Addyi, may cause a range of side effects that users should be aware of. Commonly reported side effects include dizziness, nausea, fatigue, and sleepiness. In some cases, users might experience dry mouth or insomnia. It's important for individuals considering Addyi to consult healthcare professionals for personalized advice based on their medical history and potential interactions with other medications.
Dosage Recommendations
The recommended dosage of flibanserin, marketed under the brand name Addyi in India, is typically 100 mg taken once daily at bedtime. It is important to emphasize adherence to this dosage to minimize the risk of side effects and enhance efficacy. Flibanserin is indicated for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women specifically. You should consult a healthcare professional for personalized advice and monitoring while using this medication.
Availability and Access
Flibanserin, marketed under the brand name Addyi, is available in India through various pharmaceutical suppliers and online pharmacies. Your access to this medication may vary depending on local regulations and specific health care provider prescriptions. Some health care facilities may offer consultations to determine the appropriateness of flibanserin for individuals dealing with Hypoactive Sexual Desire Disorder (HSDD). It is advisable to check with a licensed pharmacist or doctor for up-to-date information on availability and purchase options.